Yesterday, in the Nature journal, British scientists (the real ones, from Cardiff) published an interesting article. They managed to assemble T-lymphocytes that can bind to almost all types of cancer.
The technology itself is not new. CAR-T therapy involves implanting specially engineered lymphocytes with chimeric receptors targeted at a specific type of cancer and individual.
In this case, it seems they created a “universal soldier” that works across a broad range of target molecules.
This has always been a rather expensive procedure, up to 1 million dollars, partly because it requires fine-tuning. The novelty—seemingly a discovery—is only the first swallow.
It will be interesting to observe.
Hi, I'm Rauf Aliev. 